Bioluminescence Imaging of Human Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Myocardial Infarction
Myocardial infarction is a leading cause of mortality and morbidity worldwide, and current treatments fail to address the underlying scarring and cell loss, which is a major cause of heart failure after infarction. The novel strategy, therapeutic angiogenesis and/or vasculogenesis with endothelial progenitor cells transplantation holds great promise to increase blood flow in ischemic areas, thus rebuild the injured heart and reverse the heart failure. Given the potential of self-renewal and differentiation into virtually all cell types, human embryonic stem cells (hESCs) may provide an alternate source of therapeutic cells by allowing the derivation of large numbers of endothelial cells for therapeutic angiogenesis and/or vasculogenesis of ischemic heart diseases. Moreover, to fully understand the fate of implanted hESCs or hESC derivatives, investigators need to monitor the motility of cells in living animals over time. In this chapter, we describe the application of bioluminescence reporter gene imaging to track the transplanted hESC-derived endothelial cells for treatment of myocardial infarction. The technology of inducing endothelial cells from hESCs will also be discussed.
KeywordsHuman embryonic stem cells Endothelial cells Myocardial infarction Bioluminescence imaging Firefly luciferase Green fluorescent protein
This work was partially supported by grants from the National Basic Research Program of China (2011CB964903), National Natural Science Foundation of China (31071308), Tianjin Natural Science Foundation (12JCZDJC24900), NCET of State Education Ministry (NCET-12-0282) and Fundamental Research Funds for the Central Universities (65121018).
- 4.Li Z, Wilson KD, Smith B, Kraft DL, Jia F, Huang M, Xie X, Robbins RC, Gambhir SS, Weissman IL, Wu JC (2009) Functional and transcriptional characterization of human embryonic stem cell-derived endothelial cells for treatment of myocardial infarction. PLoS One 4(12):e8443. doi: 10.1371/journal.pone.0008443 PubMedCrossRefGoogle Scholar
- 7.Wang L, Su W, Liu Z, Zhou M, Chen S, Chen Y, Lu D, Liu Y, Fan Y, Zheng Y, Han Z, Kong D, Wu JC, Xiang R, Li Z (2012) CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 33(20): 5107–5114. doi: 10.1016/j.biomaterials. 2012.03.067 PubMedCrossRefGoogle Scholar
- 9.Li Z, Suzuki Y, Huang M, Cao F, Xie X, Connolly AJ, Yang PC, Wu JC (2008) Comparison of reporter gene and iron particle labeling for tracking fate of human embryonic stem cells and differentiated endothelial cells in living subjects. Stem Cells 26(4):864–873. doi: 10.1634/stemcells.2007-0843 PubMedCrossRefGoogle Scholar